Diagnostic pathways for breast cancer in 10 International Cancer Benchmarking Partnership (ICBP) jurisdictions: an international comparative cohort study based on questionnaire and... by David Weller, Usha Menon, Alina Zalounina Falborg, Henry Jensen, Andriana Barisic, Anne Kari Knudsen, David H Brewster, Victoria Cairnduff, Eva Grunfeld, Elizabeth Harland, Mats Lambe, Rebecca-Jane Law, Yulan Lin, Martin Malmberg, Donna Turner, Richard D Neal, Victoria White, Samantha Harrison, Peter Vedsted, Una MacLeod, Conan Donnelly, Anna Gavin, Jon Emery, Oliver Bucher, Jatinderpal Kalsi, Chantelle Anandan, Evangelia Ourania Fourkala, Therese Kearney, Marie-Louise Essink-Bot, Sigrun Saur Almberg, Breann Hawryluk, Jacqueline Kelly, Jackie Boylan, Jan Willem Coebergh, David Brewster, Stefan Bergström, Victoria Hammersley, Rebecca Bergin, Alina Zalounina Falborg, Andriana Barisi, Kerry Moore, Maria Rejmyr Davis

“…Data were supplemented by feedback from their primary care physicians (PCPs), cancer treatment specialists and available registry data.Primary and secondary outcome measures Patient, primary care, diagnostic and treatment intervals.Results Overall, 56% of women reported symptoms to primary care, with 66% first noticing lumps or breast changes. …”
Get full text

Gut microbiota derived DCA enhances FOLFOX efficacy via Ugt1a6b mediated enterohepatic circulation in colon cancer by Qian Fang, Xiaoying Hou, Limei Fan, Yufei Deng, Xiaoxuan Li, Hongyun Zhang, Haiping Wang, Zhengqi Fu, Binlian Sun, Xiji Shu, Hongzhi Du, Yuchen Liu

“…In conclusion, our findings establish that gut microbiota-derived DCA enhances the efficacy of FOLFOX potentially via Ugt1a6b mediated enterohepatic circulation, providing novel insights into a synergistic therapeutic strategy for improving colon cancer treatment.…”
Get full text

Curcumin-enhanced NIR-II-responsive gold nanobipyramids for targeted HSP 90 inhibition by Zhenying Diao, Youcheng Liang, Yong Liu, Dou Zhang, Long Qiu, Jianbo Sun, Qiaoyou Lu, Yanlei Liu, Daxiang Cui, Ting Yin

“…Blockade of heat shock protein 90 (HSP90) expression in multimodal synergistic therapy has a great prospect for cancer treatment. Nanomaterials combined with bioinformatic analysis provides accurate guidance for the design of anti-HSP90 nanomedicines. …”
Get full text

Local and distant response to intratumoral immunotherapy assessed by immunoPET in mice by Aurélien Marabelle, Louis Meyblum, Lambros Tselikas, Thierry de Baere, Sandrine Susini, Fréderic Deschamps, Baptiste Bonnet, Céline Chevaleyre, Benoit Jego, Dimitri Kereselidze, Vincent Lebon, Charles Truillet

“…Background Despite the promising efficacy of immune checkpoint blockers (ICB), tumor resistance and immune-related adverse events hinder their success in cancer treatment. To address these challenges, intratumoral delivery of immunotherapies has emerged as a potential solution, aiming to mitigate side effects through reduced systemic exposure while increasing effectiveness by enhancing local bioavailability. …”
Get full text

Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types by Vivek Subbiah, Samuel J Klempner, Neeraj Agarwal, David P Carbone, Amit Mahipal, Shilpa Gupta, David Fabrizio, Jeffrey S Ross, Gerald Li, David R Gandara, Miles C Andrews, Jonathan W Riess, Ramez N Eskander, Ryon P Graf, Geoffrey R Oxnard, Sarah Sammons, Jeremy Snider, Lilia Bouzit, Cheryl Cho-Phan, Megan Price, Julia C F Quintanilha, Richard Sheng Poe Huang

“…Deidentified data from electronic health records from approximately 280 cancer treatment facilities were captured into a clinico-genomic database. …”
Get full text

Astaxanthin mitigates doxorubicin-induced cardiotoxicity via inhibiting ferroptosis and autophagy: a study based on bioinformatic analysis and in vivo/vitro experiments by Bowen Yin, Jingyi Ren, Xuanyi Liu, Yadong Zhang, Jinshi Zuo, Rui Wen, Huanting Pei, Miaomiao Lu, Siqi Zhu, Zhenao Zhang, Ziyi Wang, Yanyi Zhai, Yuxia Ma

“…BackgroundDoxorubicin (DOX), a widely employed chemotherapeutic agent in cancer treatment, has seen restricted use in recent years owing to its associated cardiotoxicity. …”
Get full text

RECQL4 affects MHC class II‐mediated signalling and favours an immune‐evasive signature that limits response to immune checkpoint inhibitor therapy in patients with malignant melan... by Sara Egea‐Rodriguez, Renáta Váraljai, Thierry M. Nordmann, Restuan Lubis, Manuel Philip, Florian Rambow, Alexander Roesch, Michael Flaig, Susanne Horn, Raphael Stoll, Fang Zhao, Annette Paschen, Bert Klebl, Ian D. Hickson, Dirk Schadendorf, Matthias Mann, Iris Helfrich

“…Abstract Background Cancer immunotherapy has transformed metastatic cancer treatment, yet challenges persist regarding therapeutic efficacy. …”
Get full text

Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL by Tingting Zhang, Zhenzhen Zhang, Xiubao Ren, Jin He, Zhengzi Qian, Bin Meng, Lei Jiao, Hengqi Liu, Lanfang Li, Lihua Qiu, Shiyong Zhou, Wenchen Gong, Huilai Zhang, Xianhuo Wang

“…Background Targeting the PD-1/PD-L1/L2 (programmed cell death protein 1/programmed cell death ligand 1/ligand 2) pathway combined with other immunosuppressive signalings, such as CD73/A2aR (A2a adenosine receptor) adenosine signaling, has emerged as a promising strategy for cancer treatment. The genetic characteristics of these immune checkpoints need to be further investigated in diffuse large B-cell lymphoma (DLBCL).Methods We performed whole-exome sequencing/targeted deep sequencing to investigate the genetic characteristics of PD-1/PD-L1/L2 and CD73/A2aR. …”
Get full text

Preclinical pharmaco-toxicological screening of biomimetic melanin-like nanoparticles as a potential therapeutic strategy for cutaneous melanoma by Iasmina Marcovici, Iasmina Marcovici, Raul Chioibas, Raul Chioibas, Istvan Zupko, Iulia Pinzaru, Iulia Pinzaru, Alina Moaca, Alina Moaca, Adriana Ledeti, Adriana Ledeti, Lucian Barbu-Tudoran, Lucian Barbu-Tudoran, Andreea Geamantan, Andreea Geamantan, Iasmina Predescu, Iasmina Predescu, Cristina Adriana Dehelean, Cristina Adriana Dehelean

“…Up to date, the utilization of melanin-like nanoparticles (MEL-NPs) in cancer treatment has been well-documented, although their efficacy in CM therapy remains scarcely investigated. …”
Get full text

Risk Factors for Hospital Readmission Following Noncardiac Surgery: International Cohort Study by Michael H. McGillion, RN, PhD, Flavia K. Borges, MD, PhD, David Conen, MD, MPH, Daniel I. Sessler, MD, Brenda L. Coleman, RN, PhD, Maura Marcucci, MD, MSc, Carley Ouellette, RN, MSc, Marissa Bird, RN, PhD, Carly Whitmore, RN, PhD, Shaunattonie Henry, RN, PhD, Sandra Ofori, MD, MSc, Shirley M. Pettit, RN, Deborah M. Bedini, RN, MHS, Leslie P. Gauthier, MScT, Jennifer Lounsbury, RN(EC), MN, Nancy M. Carter, RN, PhD, Vikas Tandon, MD, Ameen Patel, MD, Teresa Cafaro, MD, MSc, Marko R. Simunovic, MD, John A. Harlock, MD, Diane Heels-Ansdell, MSc, Fadi Elias, MD, MS, Theodore Rapanos, MD, Shawn Forbes, MD, Elizabeth Peter, RN, PhD, Judy Watt-Watson, RN, PhD, Kelly Metcalfe, RN, PhD, Sandra L. Carroll, RN, PhD, Philip J. Devereaux, MD, PhD

“…Multivariable analyses demonstrated that 9 baseline characteristics (eg, cancer treatment in past 6 months; adjusted hazard ratio [HR], 1.44; 95% CI, 1.30–1.59), 5 baseline laboratory and physical measures (eg, estimated glomerular filtration rate or on dialysis; HR, 1.47; 95% CI, 1.24–1.75), 7 surgery types (eg, general surgery; HR, 1.86; 95% CI, 1.61–2.16), 5 index hospitalization events (eg, stroke; HR, 2.21; 95% CI, 1.24–3.94), and 3 other factors (eg, discharge to nursing home; HR, 1.61; 95% CI, 1.33–1.95) were associated with readmission. …”
Get full text

Development of chimeric Nanobody-Granzyme B functionalized ferritin nanoparticles for precise tumor therapy by Baijin Xia, Huolun Feng, Xinmiao Jiang, Jialing Guo, Keming Lin, Wenxing Zhang, Fan Xing, Lixue Cao, Yong Li, Hui Zhang, Xu Zhang, Wenyu Li, Fei Yu

“…Our findings highlight the potential of engineered nanoparticles as effective and targeted therapeutic agents across various tumor types, offering promising prospects for clinical translation in cancer treatment.…”
Get full text

Butyrate-engineered yeast activates Nppa and Sgcg genes and reduces radiation-induced heart damage via the gut-heart axis by Jiahao Wu, Kaihua Ji, Guangbo Kang, Manman Zhang, Jigang Wang, Lina Wang, Mengxue Gao, Xiaoxiao Jia, Xinran Lu, Yan Wang, Xinran Gao, Yufei Guo, Zhixin Zhu, Qinghua Wang, Zhenyu Zhao, Qiang Liu, He Huang

“…This study has a profound impact on cancer treatment, the emergence of engineered yeast will alleviate radiotherapy side effects and benefit patients.…”
Get full text

SPIRIT-DEFINE explanation and elaboration: recommendations for enhancing quality and impact of early phase dose-finding clinical trials protocolsResearch in context by Moreno Ursino, Guillermo Villacampa, Jan Rekowski, Munyaradzi Dimairo, Olga Solovyeva, Deborah Ashby, Jordan Berlin, Oliver Boix, Melanie Calvert, An-Wen Chan, Courtney H. Coschi, Thomas R. Jeffry Evans, Elizabeth Garrett-Mayer, Robert M. Golub, Christina Guo, Kathryn S. Hayward, Sally Hopewell, John D. Isaacs, S. Percy Ivy, Thomas Jaki, Olga Kholmanskikh, Andrew Kightley, Shing Lee, Rong Liu, Adrian Mander, Lynley V. Marshall, James Matcham, Dhrusti Patel, Richard Peck, Khadija Rerhou Rantell, Dawn P. Richards, Mahtab Rouhifard, Lesley Seymour, Yoshiya Tanaka, Christopher J. Weir, Johann de Bono, Christina Yap

Get full text

CONSORT-DEFINE explanation and elaboration: recommendations for enhancing reporting quality and impact of early phase dose-finding clinical trialsResearch in context by Jan Rekowski, Christina Guo, Olga Solovyeva, Munyaradzi Dimairo, Mahtab Rouhifard, Dhrusti Patel, Emily Alger, Deborah Ashby, Jordan Berlin, Oliver Boix, Melanie Calvert, An-Wen Chan, Courtney H. Coschi, Johann de Bono, Thomas R. Jeffry Evans, Elizabeth Garrett–Mayer, Robert M. Golub, Kathryn S. Hayward, Sally Hopewell, John D. Isaacs, S. Percy Ivy, Thomas Jaki, Olga Kholmanskikh, Andrew Kightley, Shing Lee, Rong Liu, Israel Maia, Adrian Mander, Lynley V. Marshall, James Matcham, Richard Peck, Khadija Rerhou Rantell, Dawn P. Richards, Lesley Seymour, Yoshiya Tanaka, Moreno Ursino, Christopher J. Weir, Christina Yap

Get full text

2024 update of the AGIHO guideline on diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients with solid tumours and hematological malignan... by Michael Sandherr, Jannik Stemler, Enrico Schalk, Tessa Hattenhauer, Marcus Hentrich, Bernd Hertenstein, Christian Hohmann, Sibylle C. Mellinghoff, Rebekka Mispelbaum, Christina Rieger, Martin Schmidt-Hieber, Rosanne Sprute, Guenter Weiss, Oliver A. Cornely, Larissa Henze, Cornelia Lass-Floerl, Gernot Beutel, Annika Y. Classen, Noemi F. Freise, Meinolf Karthaus, Philipp Koehler, Robert Krause, Julia Neuhann, Hans Martin Orth, Olaf Penack, Markus Schaich, Karsten Spiekermann, Sebastian Voigt, Florian Weissinger, Elena Busch

“…The implementation of standard operating procedures (SOP) across hospitals and outpatient cancer departments can improve the outcome of FN patients by reducing FN-related morbidity and mortality and by the continuation of cancer treatment. This guideline describes an evidence-based approach to risk stratification, epidemiology, diagnosis, and treatment. …”
Get full text

A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive pancreatic cancer by Peter Jung, Stefan P. Glaser, Jing Han, Alexandra Popa, Laura Pisarsky, Ningping Feng, Antonia Geyer, Franziska Haderk, Donat Alpar, Christopher Bristow, Susanne Schmittner, Paula-Elena Traexler, Mikhila Mahendra, Birgit Poehn, Poojabahen Gandhi, Roberto Fiorelli, Sanket Awate, Nicole Budano, Florian Martin, Christoph Albrecht, Barbara Drobits-Handl, Sathanandam S. Anand, Srinath Kasturirangan, Francesca Trapani, Norbert Schweifer, Joseph R. Marszalek, Ulrike Tontsch-Grunt, Mark Pearson, Timothy P. Heffernan, Norbert Kraut, Christopher P. Vellano, Juan Manuel García-Martínez

“…Exploitation of extrinsic apoptosis signaling via TRAILR2 activation represents a promising therapeutic concept in cancer treatment. The limited clinical success of previous TRAILR2 agonistic agents, to date, has been ascribed to either poor efficacy or hepatotoxicity. …”
Get full text

Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti... by Arndt Borkhardt, Nan Qin, Stephen T Keir, Darell D Bigner, Allison Cole, Matthias Wölfl, Viktoria Marquardt, Johanna Theruvath, David Pauck, Daniel Picard, Lena Blümel, Mara Maue, Jasmin Bartl, Ulvi Ahmadov, Maike Langini, Frauke-Dorothee Meyer, Joselyn Cruz-Cruz, Claus M Graef, Till Milde, Olaf Witt, Anat Erdreich-Epstein, Gabriel Leprivier, Ulf Kahlert, Anja Stefanski, Kai Stühler, Julia Hauer, Thomas Beez, Christiane B Knobbe-Thomsen, Ute Fischer, Jörg Felsberg, Finn K Hansen, Rajeev Vibhakar, Sujatha Venkatraman, Samuel H Cheshier, Guido Reifenberger, Thomas Kurz, Marc Remke, Siddhartha Mitra

“…Therefore, targeting epigenetic modifiers for cancer treatment has gained increasing interest, and inhibitors for various epigenetic modulators have been intensively studied in clinical trials. …”
Get full text

Crosstalk between Gut Microbiota and Cancer Immunotherapy: Present Investigations and Future Perspective by Yuhui Tang, Qiaoting Cai, Zhi Tian, Wenkuan Chen, Hailin Tang

“…Gut microbiota is crucial for protecting the homeostasis of immune locally and systemically, and its dysbiosis is essentially correlated to tumorigenesis, cancer progression, and refractoriness to cancer treatments, including the novel immunotherapy. Increasing evidence unravel the intricate role of gut microbiota in reshaping tumor microenvironment and affecting the efficacy and toxicities of immunotherapy, which shed more light on the future applications of gut microbiota in efficacious biomarker and combination treatment of immunotherapy. …”
Get full text

Safety of Ovarian Tissue Autotransplantation for Cancer Patients by Laurence Bockstaele, Sophie Tsepelidis, Julie Dechene, Yvon Englert, Isabelle Demeestere

“…Cancer treatments can induce premature ovarian failure in almost half of young women suffering from invasive neoplasia. …”
Get full text

Insights From Diverse Perspectives on Social Media Messages to Inform Young Adults With Cancer About Clinical Trials: Focus Group Study by Melissa P Beauchemin, Desiree Walker, Allison Rosen, Maria Frazer, Meital Eisenberger, Rhea K Khurana, Edward Bentlyewski, Victoria Fedorko, Corey H Basch, Grace C Hillyer

“… Abstract BackgroundLow rates of adolescent and young adult (YA; aged 15-39 y) clinical trial enrollment (CTE), particularly among underserved groups, have resulted in a lack of standardized cancer treatments and follow-up guidelines for this group that may limit improvement in cancer treatments and survival outcomes for YAs. …”
Get full text